GSK plc reports

6-K File 001-15170

FDA ACCEPTS AREXVY FILING FOR ADULTS 50-59 AT RISK

Filing date

06 Feb 2024

Reporting date

06 Feb 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

SHINGRIX 18+ AT RISK CHINA FILING REVIEW ACCEPTED

Filing date

06 Feb 2024

Reporting date

06 Feb 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

GSK PRESENTS POSITIVE DREAMM-7 PHASE III DATA

Filing date

06 Feb 2024

Reporting date

06 Feb 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date

01 Feb 2024

Reporting date

01 Feb 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

TOTAL VOTING RIGHTS

Filing date

01 Feb 2024

Reporting date

01 Feb 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

STATEMENT: ZANTAC (RANITIDINE) LITIGATION

Filing date

01 Feb 2024

Reporting date

01 Feb 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

FINAL RESULTS

Filing date

31 Jan 2024

Reporting date

31 Jan 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

4 File 001-37627

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filing date

30 Jan 2024

Reporting date

07 Dec 2023

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

EMA ACCEPTS AREXVY FILING FOR ADULTS 50-59 AT RISK

Filing date

29 Jan 2024

Reporting date

29 Jan 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

EUROPEAN COMMISSION AUTHORISES OMJJARA IN THE EU

Filing date

29 Jan 2024

Reporting date

29 Jan 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

SC 13D/A

AMENDMENT TO FORM SC 13D

Filing date

19 Jan 2024

Reporting date

Not listed

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date

19 Jan 2024

Reporting date

19 Jan 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date

17 Jan 2024

Reporting date

17 Jan 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

CURRENT REPORT

Filing date

17 Jan 2024

Reporting date

16 Jan 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

GSK COMPLETES SALE OF SHARES IN HALEON PLC

Filing date

17 Jan 2024

Reporting date

17 Jan 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date

16 Jan 2024

Reporting date

16 Jan 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

NUCALA APPROVED IN CHINA FOR USE IN SEVERE ASTHMA

Filing date

10 Jan 2024

Reporting date

10 Jan 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

GSK ENTERS AGREEMENT TO ACQUIRE AIOLOS BIO

Filing date

09 Jan 2024

Reporting date

09 Jan 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

TOTAL VOTING RIGHTS

Filing date

02 Jan 2024

Reporting date

02 Jan 2024

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date

21 Dec 2023

Reporting date

21 Dec 2023

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

JEMPERLI PLUS ZEJULA TRIAL MEETS ENDPOINT

Filing date

18 Dec 2023

Reporting date

18 Dec 2023

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date

13 Dec 2023

Reporting date

13 Dec 2023

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

JAPAN ACCEPTS AREXVY FILING FOR AT RISK ADULTS

Filing date

12 Dec 2023

Reporting date

11 Dec 2023

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

JEMPERLI PLUS CHEMOTHERAPY EU AUTHORISATION

Filing date

11 Dec 2023

Reporting date

11 Dec 2023

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-15170

GSK PUBLISHES PROVISIONAL 2024 DIVIDEND DATES

Filing date

04 Dec 2023

Reporting date

04 Dec 2023

SEC evidence

Open document Open filing

Next action

Verify source filing